Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Capital Leases: 2019-2020

Historic Capital Leases for Burning Rock Biotech (BNR) over the last 1 years, with Dec 2020 value amounting to $738,000.

  • Burning Rock Biotech's Capital Leases rose 8.01% to $738,000 in Q4 2020 from the same period last year, while for Dec 2020 it was $738,000, marking a year-over-year increase of 8.01%. This contributed to the annual value of $738,000 for FY2020, which is 5.81% up from last year.
  • Per Burning Rock Biotech's latest filing, its Capital Leases stood at $738,000 for Q4 2020, which was down 5.51% from $781,000 recorded in Q3 2020.
  • Burning Rock Biotech's Capital Leases' 5-year high stood at $781,000 during Q3 2020, with a 5-year trough of $683,298 in Q4 2019.
  • Moreover, its 2-year median value for Capital Leases was $734,000 (2020), whereas its average is $733,074.
  • Data for Burning Rock Biotech's Capital Leases shows a peak YoY climbed of 8.01% (in 2020) over the last 5 years.
  • Burning Rock Biotech's Capital Leases (Quarterly) stood at $683,298 in 2019, then rose by 8.01% to $738,000 in 2020.
  • Its Capital Leases stands at $738,000 for Q4 2020, versus $781,000 for Q3 2020 and $730,000 for Q2 2020.